A meta-analysis to estimate the "real" placebo effect in juvenile idiopathic arthritis (JIA) trials by Martini A, Palmisani E, Ravelli A, Galasso R, Ruperto N, Demirkaya E, Pistorio A

Connect to this object online.

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with meth... by Hirani SP, Kassoumeri L, Mulligan K, Ruperto N, Woo P, Wedderburn LR, Newman SP

Connect to this object online.

Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA) by Hirani SP, Kassoumeri L, Etheridge A, Mulligan K, Ruperto N, Woo P, Wedderburn L, Newman SP

Connect to this object online.

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA) by Davì S, Consolaro A, Ferrari C, Federici S, Vitale R, Filocamo G, Loy A, Ruperto N, Martini A, Ravelli A

Connect to this object online.

Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA) by Magnani A, Oliveira S, Castell E, Arguedas O, Ullmann N, Pederzoli S, Manzoni S Magni, Pistorio A, Ruperto N, Martini A, Ravelli A

Connect to this object online.

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis by Bertamino M, Filocamo G, Consolaro A, Palmisani E, Bracciolini G, Suffia C, Muratore V, Ruperto N, Martini A, Ravelli A

Connect to this object online.

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA) by Filocamo G, Schiappapietra B, Manzoni S Magni, Lanni S, Solari N, Viola S, Pistorio A, Ruperto N, Tani D, Martini A, Ravelli A

Connect to this object online.

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis by Meiorin S, Filocamo G, Palmisani E, Sala I, Manzoni S Magni, Lanni S, Viola S, Buoncompagni A, Pistorio A, Ruperto N, Martini A, Ravelli A

Connect to this object online.

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J... by Ruperto N, Quartier P, Wulffraat N, Woo P, Loy A, Mouy R, Bader-Meunier B, Prakken B, Noseda E, Rordorf C

Connect to this object online.

Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD) by Palmisani E, Filocamo G, Saad-Magalhaes C, Consolaro A, Magni-Manzoni S, Viola S, Pistorio A, Ruperto N, Tani D, Serpico S, Martini A, Ravelli A

Connect to this object online.

Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients by Solari N, Filocamo G, Schiappapietra B, Consolaro A, Magni-Manzoni S, Viola S, Ruperto N, Saad-Magalhaes C, Tani D, Serpico S, Martini A, Ravelli A

Connect to this object online.

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS) by Consolaro A, Ruperto N, Bazso A, Magni-Manzoni S, Pelagatti MA, Pistorio A, Magnani A, Malattia C, D'Agostino I, Filocamo G, Martini A, Ravelli A

Connect to this object online.

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept by Ruperto N, Lovell DJ, Li T, Paz E, Horneff G, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Nunez AF, Sigal L, Block A, Covucci A, Martini A, Giannini EH

Connect to this object online.

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients by Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH

Connect to this object online.

Therapeutic approaches for the treatment of new onset and flared juvenile systemic lupus erythematosus with active renal disease: an international multicenter PRINTO study by Palmisani E, Sztajnbok F, Porras O, Ozen S, Cortis E, Pasic S, Espada G, Mihaylova D, Cuttica R, Alessio M, Oliveira S, Ravelli A, Pistorio A, Miettunen P, Martini A, Ruperto N

Connect to this object online.

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis by Wouters C, McIlraith MJ, Ilowite N, Chalom E, Jones OY, Koné-Paut I, Higgins G, Gamir M, Reiff A, Lovell DJ, Ruperto N, Liu S, Kupper H, Giannini EH, Martini A

Connect to this object online.

Prevalence of monogenic autoinflammatory diseases among Pediatric Rheumatology centers: the Eurofever PReS/PRINTO survey by Gattorno M, Frenkel J, Ozen S, De Benedetti F, Konè-Paut I, Neven N, Girschick H, Özdogan H, Wouters C, Woo P, Hofer M, Dolezalova P, Toplak N, Richard V, Martini A, Ruperto N

Connect to this object online.

The PRINTO provisional definition of remission in juvenile dermatomyositis by Kasapcopur O, Ganser G, Ferriani V, Penades I, Dolezalova P, Quartier P, Hofer M, Garay S, Wulffraat N, Pilkington C, Malattia C, Ravelli A, Miettunen P, Pistorio A, Lazarevic D, Melo-Gomes JA, Wierzbowska M, Martini A, Ruperto N

Connect to this object online.

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... by McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ

Connect to this object online.

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatme... by Ruperto N, Lovell DJ, Cuttica R, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH

Connect to this object online.